The test, the first-ever to distinguish the type 1 form of diabetes, could detect the ZnT8 autoantibody in 65 percent of the samples from patients with diagnosed type 1 diabetes and gave false positive results in less than two percent of the samples from patients diagnosed with other disease.

On the second day of “Patient-Centered Diabetes Care: Putting Theory Into Practice,” Jan Berger, MD, MJ, president of Health Intelligence Partners, moderated the panel discussion “Measuring the Impact of Pharmacists in Diabetes Patient Care."

Coverage of the 73rd Scientific Sessions of the American Diabetes Association.

With the unveiling of the first FDA-approved system with the name "artificial pancreas," Medtronic will seek a new CMS code that would cover both the insulin pump and the continuous glucose monitoring parts of the process, according to the company.

With speculation about an artificial pancreas rising, the September edition of Evidenced-Based Diabetes Management looked at the three systems that were being considered by the FDA including the threshold suspend technology Medtronic announced Friday and asked the next questions: Assuming the technology is approved, will insurers pay for it? How will this potentially life-altering advance make its way into the hands of the persons with diabetes who need it most?